Abstract
Chemotherapy for acute toxoplasmosis has classically relied on inhibitors of the folate metabolic pathway (Brooks et al. 1987), typically a synergistic combination of sulfonamides (inhibitors of dihydropteroate synthase, which produces folic acid) and inhibitors of dihydrofolate reductase (e.g., pyrimethamine). Unfortunately, the combination of pyrimethamine and sulfonamides has been less successful against toxoplasmic encephalitis associated with acquired immunodeficiency syndrome (AIDS) (Luft and Remington 1992). Chronic treatment must be maintained to guard against the re-emergence of parasites from latent tissue cysts, as the bradyzoite forms are insensitive to most metabolic inhibitors. Long-term sulfonamide administration often produces a severe hypersensitivity response, however, and pyrimethamine alone is usually insufficient to prevent relapse; prolonged pyrimethamine therapy may also result in bone marrow depression (Haverkos 1987; Leport et al. 1988; Tenant-Flowers et al. 1991). Moreover, reliance on chronic treatment raises the fear that drug-resistant parasites may emerge. These concerns have lent renewed impetus to the development of improved treatment protocols, the identification of novel parasiticidal agents, and studies on the metabolism of the parasite, with an eye toward more effective drug therapy (Laughon et al. 1991).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Araujo FG, Remington JS (1992) Recent advances in the search for new drugs for treatment of toxoplasmosis. Int J Antimicrob Agents 1:153–164
Beckers CJ, Roos DS, Donald RG, Luft BJ, Schwab JC, Cao Y, Joiner KA (1995) Inhibition of cytoplasmic and organellar protein synthesis in Toxoplasma gondii. Implications for the target of macrolide antibiotics. J Clin Invest 95:367–376
Black M, Seeber F, Soldati D, Kim K, Boothroyd JC (1995) Restriction enzyme-mediated integration elevates transformation frequency and enables cotransfection of Toxoplasma gondii. Mol Biochem Parasitol 74:55–63
Bohne W, Gross U, Ferguson DJP, Heesemann J (1995) Cloning and characterization of a bradyzoite-specifically expressed gene (HSP30/BAG1) of Toxoplasma gondii, related to genes encoding small heat-shock proteins of plants. Mol Microbiol 16:1221–1230
Boothroyd JC, Black M, Kim K, Pfefferkorn ER, Seeber F, Sibley LD, Soldati D (1995) Forward and reverse genetics in the study of the obligate, intracellular parasite Toxoplasma gondii. In: Adolph K (ed) Methods in Molecular Genetics. Academic, New York, pp 3–29
Brooks RG, Remington JS, Luft BJ (1987) Drugs used in the treatment of toxoplasmosis. Antimicrob Agents Annu 2:297–306
Cotrim PC, Garrity LK, Beverly SM (1994) Isolation of drug resistance genes in Leishmania major by transfection using a shuttle cosmid vector. Molecular Parasitology Meeting, 18–22 September 1994, Woods Hole, MA, abstract 125C
Danneman B, McCutchan JA, Israelski D, Antoniskis D, and the California Collaborative Treatment Group (1992) Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus clindamycin. Ann Int Med 116:33–43
Donald RGK, Roos DS (1993) Stable molecular transformation of Toxoplasma gondii: a selectable dihydrofolate reductase-thymidylate synthase marker based on drug-resistance mutations in malaria. Proc Natl Acad Sci USA 90: 11703–11707
Donald RGK, Carter D, Ullman B, Roos DS (1996) Insertional tagging, cloning and expression of the Toxoplasma gondii hypoxanthine-xanthine-guanine phosphoribosyltransferase gene: use as a selectable marker for stable transfection. J Biol Chem (in press)
Donald RGK, Roos DS (1994) Homologous recombination and gene replacement at the DHFR-TS locus in Toxoplasma gondii. Mol Biochem Parasitol 63:243–253
Donald RGK, Roos DS (1995) Insertional mutagenesis in a protozoan parasite: Direct cloning of the uracil phosphoribosyl transferase gene from Toxoplasma gondii. Proc Natl Acad Sci USA 92:5749–5753
Ellis J, Griffin H, Morrison D, Johnson AM (1993) Analysis of dinucleotide frequency and codon usage in the phylum Apicomplexa. Gene 126: 163–170
Fichera ME, Bhopale MK, Roos DS (1995) In vitro assays elucidate peculiar kinetics of clindamycin action against Toxoplasma gondii. Antimicrob Agents Chemother 39: 1530–1537
Haverkos HW (1987) Assessment of therapy for toxoplasma encephalitis. Am J Med 82:907–914
High KP, Joiner KA, Handschumacher RE (1994) Isolation, cDNA sequences, and biochemical characterization of the major cyclosporin-binding proteins of Toxoplasma gondii. J Biol Chem 269:9105–9112
Katlama C (1991) Evaluation of the efficacy and safety of clindamycin and pyrimethamine for induction and maintenance therapy of toxoplasmic encephalitis in AIDS. Eur J Clin Microbiol Infect Dis 10: 189–191
Kim K, Soldati D, Boothroyd JC (1993) Gene replacement in Toxoplasma gondii with chloramphenicol acetyltransferase as selectable marker. Science 262:911–914
Laughon BE, Allaudeen HS, Becker JM, Current WL, Feinberg J, Frenkel JK, Hafner R, Hughes WT, Laughlin CA, Meyers JD, Schrager LK, Young LS (1991) Summary of the workshop on future directions in discovery and development of therapeutic agents for opportunistic infections associated with AIDS. J Infect Dis 164:244–251
Leport C, Raffi F, Katlama C, Regnier B, Saimot AG, Marche C, Vedrenne C, Vilde JL (1988) Treatment of central nervous system toxoplasmosis with pyrimethamine/sulfonamide combination in 35 patients with the acquired immunodeficiency syndrome. Am J Med 84:94–100
Luft BJ, Remington JS (1992) Toxoplasmic encephalitis in AIDS. Clin Infect Dis 15:211–222
Mortensen R (1993) Overview of gene-targeting by homologous recombination. In: Ausubel FM (ed) Current protocols in molecular biology. Wiley, Cambridge, Chap. 9.15.1–9.15.6
Parent SA, Fenimore CM, Bostian KA (1985) Vector systems for the expression, analysis and cloning of DNA sequences in S. cerevisiae. Yeast 1:83–138
Parmley SF, Yang S, Harth G, Sibley LD, Sucharczuk A, Remington JS (1994) Molecular characterization of a 65-kilodalton Toxoplasma gondii antigen expressed abundantly in the matrix of tissue cysts. Mol Biochem Parasitol 66:283–296
Pashley TV, Delves CJ, Hyde JE, Sims PFG (1995) Molecular cloning and sequence analysis of the Toxoplasma gondii dihydropteroate synthase gene. Molecular Parasitology Meeting, 17–21 September 1995, Woods Hole, MA abstract 442
Pfefferkorn ER (1990) Cell biology of Toxoplasma gondii. In: Wyler DJ (ed) Modern parasite biology. Freeman, New York, pp 26–50
Pfefferkorn ER, Borotz SE (1994) Comparison of mutants of Toxoplasma gondii selected for resistance to azithromycin, spiramycin, or clindamycin. Antimicrob Agents Chemother 38:31–37
Pfefferkorn ER, Pfefferkorn LC (1979) Quantitative studies on the mutagenesis of Toxoplasma gondii. J Parasitol 65:364–370
Pfefferkorn ER, Pfefferkorn LC (1980) Toxoplasma gondii: Genetic recombination between drugresistant mutants. Exp Parasitol 50:305–316
Ricketts AP, Pfefferkorn ER (1993) Toxoplasma gondii: Susceptibility and development of resistance to anticoccidial drugs in vitro. Antimicrob Agents Chemother 37:2358–2363
Roos DS (1993) Primary structure of the fused dihydrofolate reductase/thymidylate synthase gene of Toxoplasma gondii. J Biol Chem 268:6269–6280
Roos DS, Donald RGK, Morrissette NS, Moulton ALC (1994) Molecular tools for genetic dissection of the protozoan parasite Toxoplasma gondii. Methods Cell Biol 45:27–63
Sibley LD, LeBlanc AJ, Pfefferkorn ER, Boothroyd JC (1992) Generation of a restriction fragment length polymorphism linkage map for Toxoplasma gondii. Genetics 132: 1003–1015
Sibley LD, Messina M, Niesman IR (1994) Stable DNA transformation in the obligate intracellular parasite Toxoplasma gondii by complementation of tryptophan auxotrophy. Proc Natl Acad Sci USA 91:5508–5512
Soldati D, Boothroyd JC (1993) Transient transfection and expression in the obligate intracellular parasite Toxoplasma gondii. Science 260:349–352
Soldati D, Boothroyd JC (1995) A selector of transcription initiation in the protozoan parasite Toxoplasma gondii. Mol Cell Biol 15:87–93
Steigbigel NH (1990) Erythromycin, lincomycin and clindamycin. In: Mandel GL, Douglas RG Jr, Bennet JE (eds) Principles and practice of infectious diseases. Churchill Livingstone, New York
Stokkermans TJW, Schwartzman JD, Keenan K, Morisette NS, Tilney LG, Roos DS. Inhibition of Toxoplasma gondii replication by dinitroaniline herbicides. Exp Parasitol (in press)
Tenant-Flowers M, Boyle MJ, Carey D, Marriott DJ, Harkness JL, Penny R, Cooper DA (1991) Sulfadiazine desensitization in patients with AIDS and cerebral toxoplasmosis. AIDS 5:311–315
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Roos, D.S. (1996). Molecular Genetic Tools for the Identification and Analysis of Drug Targets in Toxoplasma gondii . In: Gross, U. (eds) Toxoplasma gondii. Current Topics in Microbiology and Immunology, vol 219. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-51014-4_22
Download citation
DOI: https://doi.org/10.1007/978-3-642-51014-4_22
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-51016-8
Online ISBN: 978-3-642-51014-4
eBook Packages: Springer Book Archive